{
    "clinical_study": {
        "@rank": "85636", 
        "acronym": "GORTEC-ELAN-RT", 
        "arm_group": [
            {
                "arm_group_label": "Standard RT", 
                "arm_group_type": "Active Comparator", 
                "description": "70 Gy / 7 weeks / 2 Gy per fraction"
            }, 
            {
                "arm_group_label": "Hypofractionated RT", 
                "arm_group_type": "Experimental", 
                "description": "55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized comparison between standard radiotherapy and hypofractionated split course\n      schedule. Compared to standard radiotherapy, the investigators expect that hypofractionated\n      split course (interruption of 2 weeks) radiotherapy will improve compliance to treatment,\n      acute tolerance of treatment, preservation of autonomy, prevention of malnutrition, with the\n      same efficacy, measured by the locoregional control rate."
        }, 
        "brief_title": "Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 70 or over\n\n          -  SIOG group 2 (vulnerable)\n\n          -  Life expectancy > 12 weeks\n\n          -  PS < 2\n\n          -  Histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral\n             cavity, oropharynx, nasopharynx, hypopharynx, larynx, cervical nodes (unknown\n             primary).\n\n          -  First line treatment\n\n          -  At least one measurable lesion (RECIST)\n\n          -  Stage II to IV\n\n          -  Patients unsuitable for surgery of the primary tumour: non resectable tumor,\n             anesthesia contra indication, patient's refusal, or organ sparing approach. Cervical\n             nodes dissection authorized\n\n          -  Patients planned to be treated in a curative intent with radiotherapy alone on\n             primary tumor site and on at least one head and neck node area\n\n          -  Consent form signed\n\n        Exclusion Criteria:\n\n          -  Primary squamous cell carcinoma of sinus, the skin or of the salivary glands\n\n          -  Stage I cancer\n\n          -  Radiotherapy planned on primary tumor only, or on neck nodes only. For patients with\n             metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma,\n             patients will be excluded if head and neck mucosa (oropharynx, larynx, hypopharynx)\n             is not included as a target volume for radiotherapy\n\n          -  Prior radiotherapy of head and neck area\n\n          -  Concurrent chemotherapy or immunotherapy or hormonotherapy\n\n          -  Induction chemotherapy\n\n          -  Concomitant infection requiring IV antibiotics\n\n          -  cancer other than head and neck cancer within the previous 5 years (baso cellular\n             skin carcinoma and cervix carcinoma excepted)\n\n          -  conditions that could lead to bad compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "202", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01864850", 
            "org_study_id": "GORTEC ELAN-RT"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard RT", 
                "description": "70 Gy / 7 weeks / 2 Gy per fraction", 
                "intervention_name": "Standard RT", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Hypofractionated RT", 
                "description": "55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy", 
                "intervention_name": "Hypofractionated RT", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HNSCC", 
            "Elderly", 
            "Geriatry"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "link": {
            "description": "GORTEC", 
            "url": "http://www.gortec.fr/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "yungan.tao@igr.fr", 
                    "last_name": "Yungan TAO, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "investigator": {
                    "last_name": "Yungan TAO, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cecile.ortholan@chpg.mc", 
                    "last_name": "Cecile ORTHOLAN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Monaco", 
                        "country": "Monaco", 
                        "zip": "98 000"
                    }, 
                    "name": "Centre Hospitalier Princesse Grace"
                }, 
                "investigator": {
                    "last_name": "Cecile ORTHOLAN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Monaco"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma", 
        "overall_contact": {
            "email": "cecile.ortholan@chpg.mc", 
            "last_name": "Cecile ORTHOLAN, MD"
        }, 
        "overall_contact_backup": {
            "email": "gortec@orange.fr", 
            "last_name": "Nadejda VINTONENKO, PhD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patient alive with locoregional control at 6 months after the end of radiotherapy", 
            "measure": "Locoregional control", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01864850"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Acute toxicity according to the CTC NCI V4 - rate of toxicity by type and by grade", 
                "measure": "Acute toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Late toxicity according to the RTOG late toxicity scale - rate of toxicity by type and by grade", 
                "measure": "Late toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Autonomy according to ADL scale", 
                "measure": "Autonomy", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Quality of life according to EORTC QLQ-C30 and QLQ-HN35", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Overall survival", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Locoregional progression", 
                "measure": "Locoregional progression", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "metastasis progression", 
                "measure": "metastasis progression", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Progression free survival", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Groupe Oncologie Radiotherapie Tete et Cou", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Groupe Oncologie Radiotherapie Tete et Cou", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}